

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|--------------------|---|------------------------|------------------|
| APPLICANTS : | Bacopoulos, et al. | CONFIRMATION NUMBER : | 5497 |
| SERIAL NUMBER : | 10/567,953 | EXAMINER : | Not yet assigned |
| I.A. FILING DATE : | August 12, 2004 | INT'L APPLICATION NO : | PCT/US04/26161 |
| PRIORITY DATE : | August 29, 2003 | ART UNIT : | Not yet assigned |
| FOR : | Combination Methods of Treating Cancer | | |

MAIL STOP PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and U.S. publications are not required.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **24852-502 NATL**, Customer No. **35437**.

Respectfully submitted,

Dated: January 3, 2007

Michelle A. Iwamoto

Ivor R. Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys/Agents for Applicants
c/o MINTZ, LEVIN, *et al.*
666 Third Avenue-24th Floor
New York, New York 10017
Telephone: (212) 983-3000
Telefax: (212) 983-3115

Please type a plus sign (+) in this box

+

PTO/SB (12-97)
 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | |
|---|--|----------------------------------|-------------------------|
| Modified Form 1449/PTO | | Application Number | 10/567,953 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | International Application Number | PCT/US04/26161 |
| | | I.A. Filing Date | August 12, 2004 |
| | | Priority Date | August 29, 2003 |
| | | First Named Inventor | Bacopoulos |
| | | Group Art Unit / Conf. No.: | Not Yet Assigned / 5497 |
| | | Examiner Name | Not Yet Assigned |
| | | Attorney Docket Number | 24852-502 NATL |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|-------------|
| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date |
| | A1 | 5,369,108 | 11/29/04 | Breslow, et al. | 514 | 266 | 10/04/91 |
| | A2 | 6,511,990 | 01/28/03 | Breslow, et al. | 514 | 314 | 08/24/00 |
| | A3 | 6,811,788 | 11/02/04 | Yu | 424 | 278 | 01/17/01 |
| | A4 | 2002/0044919 | 04/18/02 | Yu | 424 | 85.1 | 01/17/01 |
| | A5 | 2003/0059812 | 03/27/03 | Richon, et al. | 435 | 6 | 06/14/02 |
| | A6 | 2003/0096777 | 05/22/03 | Besterman, et al. | 514 | 44 | 05/14/02 |
| | A7 | 2003/0114525 | 06/19/03 | Kammer, et al. | 514 | 557 | 05/20/02 |
| | A8 | 2003/0144340 | 07/31/03 | Long, et al. | 514 | 422 | 09/26/02 |
| | A9 | 2003/0235588 | 12/25/03 | Richon, et al. | 424 | 146.1 | 02/14/03 |
| | A10 | 2004/0116407 | 06/17/04 | Boris, et al. | 514 | 217 | 07/11/03 |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|----------|---------------------------------------|-------------------------------------|---------------------|----------------|
| Exam Initials | Cite No. | Foreign Patent Document Office Number | Name of Patentee(s) or Applicant(s) | Date of Publication | English Yes No |
| | B1 | WO 2004/103358 A2, A3 | Novartis AG/Novartis Pharma GmbH | December 2, 2004 | X |
| | B2 | WO 2005/023179 A2, A3 | Aton Pharma, Inc./Sloan-Kettering | March 17, 2005 | X |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|---|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | C1 | Butler, et al. "The Histone Deacetylase Inhibitor SAHA Arrests Cancer Cell Growth, Up-Regulates Thioredoxin-Binding Protein-2, and Down-Regulates Thioredoxin"; <i>Proc. Natl. Acad. Sci. USA</i> ; Vol. 99, No. 18, pp. 11700-11705 (September 3, 2002). |
| | C2 | Castro-Galache, et al. "Susceptibility of Multidrug Resistance Tumor Cells to Apoptosis Induction by Histone Deacetylase Inhibitors"; <i>Int. J. Cancer</i> , Vol. 104, pp. 579-586 (2003). |
| | C3 | Henderson, et al. "Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)"; <i>The Journal of Biological Chemistry</i> ; Vol. 278, No. 14, pp. 12579-12589 (April 4, 2003). |
| | C4 | Kelly, et al. "Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously"; <i>Clinical Cancer Research</i> ; Vol. 9, No. 10, pp. 3578-3588 (September 1, 2003). |
| | C5 | Kim, et al. "Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA"; <i>Cancer Research</i> ; Vol. 63, pp. 7291-7300 (November 1, 2003). |
| | C6 | Peart, et al. "Novel Mechanisms of Apoptosis Induced by Histone Deacetylase Inhibitors"; <i>Cancer Research</i> , Vol. 63, pp. 4460-4471 (August 1, 2003). |
| | C7 | Zhu, et al. "The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells"; <i>Curr. Med. Chem.-Anti-Cancer Agents</i> ; Vol. 3, No. 3, pp. 187-199 (2003). |
| | C8 | International Search Report for PCT/US04/26161 mailed April 6, 2005. |

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.